New York, August 25, 2015 -- Moody's Investors Service placed the ratings of U.S. Renal Care, Inc. ("U.S. Renal") under review for downgrade, including the company's B2 Corporate Family Rating and B2-PD Probability of Default Rating. The rating action follows the announcement on August 24, 2015, that U.S. Renal entered into a definitive merger agreement with Dialysis Newco, Inc. ("DSI Renal"). Following the close of the transaction, DSI Renal's ratings will be withdraw. The financial terms and proposed new capital structure have not been announced.

Vollständigen Artikel bei Moodys lesen